CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 142 enrolled
Drug / intervention
d-cycloserine +2 moredrug
Likely dose
d-cycloserine 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01411774
NCT01411774Phase 3Completed

1/2 D-cycloserine Augmentation of CBT for Pediatric OCD

University of South Florida·interventional·Posted Aug 8, 2011·Updated Jan 23, 2018

In Brief

A Phase 3 clinical trial evaluating Cognitive-behavioral therapy, d-cycloserine, and 1 other intervention for Obsessive-compulsive Disorder. Completed, enrolled 142 participants across 2 sites.

Detailed Summary

The investigators are conducting a randomized double-blind placebo-controlled study to assess the efficacy of d-cycloserine augmentation of cognitive-behavioral therapy for the treatment of pediatric obsessive compulsive disorder. This study represents an innovative approach in translating bench research findings into clinical research and testing a new approach for optimizing an effective psychotherapy with a safe non-psychotropic medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2011
Enrollment StartJun 1, 2011
Primary CompletionJun 1, 2016
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 14.9 years ago

Interventions

Cognitive-behavioral therapybehavioral

All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.

d-cycloserinedrug

D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.

Pill placebodrug

The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).